Moleculin Biotech
MBRX
1 hedge funds and large institutions have $213K invested in Moleculin Biotech in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.41% more ownership
Funds ownership: 0.36% → 0.77% (+0.41%)
32% less capital inflows, than outflows
Capital inflows: $134K | Capital outflows: $197K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$134K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ING Group
Amsterdam,
Netherlands
|
-$122K |
| 2 |
Virtu KCG Holdings
New York
|
-$66K |
| 3 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$9K |
MBRX Hedge Fund Activity: Q4 2016 in Review
1 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2016, worth a combined $213K — down 16% from $254K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new MBRX positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Bank of America, opening a new position worth an estimated $134K. The largest seller was ING Group, cutting an estimated $122K.
- 1 institutional investor held Moleculin Biotech (MBRX) as of Q4 2016, up from 0 in Q3 2016.
- Funds reported $213K of Moleculin Biotech stock for Q4 2016, down 16% quarter-over-quarter.
- 1 fund opened new Moleculin Biotech positions in Q4 2016 and 0 closed out, a net change of +1 holder.
- The largest Moleculin Biotech buyer in Q4 2016 was Bank of America, an estimated $134K added.
- The largest Moleculin Biotech seller in Q4 2016 was ING Group, an estimated $122K sold.
Based on aggregated 13F filings for Q4 2016.